Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis

Linagliptin Regulates the Mitochondrial Respiratory Reserve to Alter Platelet Activation and Arterial Thrombosis

Background: The pharmacological inhibition of dipeptidyl peptidase-4 (DPP-4) potentiates incretin action, and DPP-4 is a drug target for type 2 diabetes and reducing cardiovascular risk. However, little is known about the non-enteroendocrine pathways by which DPP-4 might contribute to ischaemic card...

Full description

Bibliographic Details
Main Authors:	Yi Li, Rong Li, Ziqian Feng, Qin Wan, Jianbo Wu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2020-11-01
Series:	Frontiers in Pharmacology
Subjects:	dipeptidyl peptidase-4 linagliptin, cyclic AMP, mitochondria, phosphodiesterases
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2020.585612/full

Similar Items

Alternate-day dosing of linagliptin in type 2 diabetes patients controlled on once daily dose: A case series
by: Manash P Baruah, et al.
Published: (2016-01-01)

Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
by: Vladimer Darsalia, et al.
Published: (2019-05-01)

Post-marketing Study of Linagliptin: A Pilot Study
by: Gabrielle Kéfrem Alves Gomes, et al.
Published: (2019-05-01)

A case of irritant contact dermatitis and suspected linagliptin-induced koebnerized bullous pemphigoid
by: Austin Ambur, DO, et al.
Published: (2020-04-01)

Comparison of adherence and persistence among adults with type 2 diabetes mellitus initiating saxagliptin or linagliptin
by: Farr AM, et al.
Published: (2016-08-01)

Linagliptin is associated to increased treatment adherence and satisfaction in elderly outpatients with diabetes and advanced chronic kidney disease
by: Franco Gregorio, et al.
Published: (2016-11-01)

Initial combination therapy for patients with type 2 diabetes mellitus: considerations for metformin plus linagliptin
by: Jeffrey Freeman
Published: (2013-08-01)

Micro-Environmental Signature of The Interactions between Druggable Target Protein, Dipeptidyl Peptidase-IV, and Anti-Diabetic Drugs
by: Chiranjib Chakraborty, et al.
Published: (2017-01-01)

Linagliptin and cardiovascular outcomes in type 2 diabetes after acute coronary syndrome or acute ischemic stroke
by: Yan-Rong Li, et al.
Published: (2018-01-01)

Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
by: Han E, et al.
Published: (2020-11-01)

Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study
by: Vaishali Deshmukh, et al.
Published: (2015-01-01)

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin
by: Yoshia Miyawaki, et al.
Published: (2018-10-01)

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
by: Julio Rosenstock, et al.
Published: (2018-03-01)

Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study
by: Jaehyun Bae, et al.
Published: (2016-03-01)

Anti-Inflammatory Action of Sitagliptin and Linagliptin in Doxorubicin Nephropathy
by: Chor Ho Jo, et al.
Published: (2018-06-01)

SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01)

DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
by: Erna Kristin
Published: (2016-12-01)

DIPEPTIDYL DIPEPTIDASE-4: VIEW OF THE CLINICAL PHARMACOLOGIST
by: N. B. LAZAREVA
Published: (2016-12-01)

Synthesis and Characterization of Process-Related Impurities of Antidiabetic Drug Linagliptin
by: Yiwen Huang, et al.
Published: (2016-08-01)

Predictive Clinical Parameters and Glycemic Efficacy of Vildagliptin Treatment in Korean Subjects with Type 2 Diabetes
by: Jin-Sun Chang, et al.
Published: (2013-02-01)

Palpable Purpura in a Patient with Uncontrolled Type 2 Diabetes Mellitus: Possible Side Effect of Linagliptin
by: Ömercan Topaloğlu, et al.
Published: (2019-03-01)

Dipeptidyl peptidase IV and its implication in cancer
by: Yarini M Arrebola, et al.

Renal insufficiency and linagliptin therapy: a case report
by: Anna Corsi, et al.
Published: (2018-09-01)

Neuroprotective Properties of Linagliptin: Focus on Biochemical Mechanisms in Cerebral Ischemia, Vascular Dysfunction and Certain Neurodegenerative Diseases
by: Michał Wiciński, et al.
Published: (2019-08-01)

Preferential prescribing of linagliptin in type 2 diabetes patients in an expanded post‐marketing surveillance study in Japan
by: Soulmaz Fazeli Farsani, et al.
Published: (2019-09-01)

Which is better, high‐dose metformin monotherapy or low‐dose metformin/linagliptin combination therapy, in improving glycemic variability in type 2 diabetes patients with insufficient glycemic control despite low‐dose metformin monotherapy? A randomized, cross‐over, continuous glucose monitoring‐based pilot study
by: Hiroshi Takahashi, et al.
Published: (2019-05-01)

Abnormal Mitochondrial cAMP/PKA Signaling Is Involved in Sepsis-Induced Mitochondrial and Myocardial Dysfunction
by: Remi Neviere, et al.
Published: (2016-12-01)

The effect of sitagliptin on hepatic ischemic reperfusion injury in rats
by: Song-Chol Mun, et al.
Published: (2020-01-01)

A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers
by: Kang WY, et al.
Published: (2020-05-01)

Linagliptin in the frail elderly diabetic patient
by: Eva Palmieri
Published: (2018-09-01)

CHARACTERIZATION OF LINAGLIPTIN USING ANALYTICAL TECHNIQUES
by: Amanda Thomas Barden, et al.
Published: (2017-12-01)

Analytical Enantio-Separation of Linagliptin in Linagliptin and Metformin HCl Dosage Forms by Applying Two-Level Factorial Design
by: Sushant B. Jadhav, et al.
Published: (2016-10-01)

The NO/cGMP pathway inhibits transient cAMP signals through the activation of PDE2 in striatal neurons
by: Marina ePolito, et al.
Published: (2013-11-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
by: Masako Uchii, et al.
Published: (2017-11-01)

Evaluation of Modulators of cAMP-Response in Terms of Their Impact on Cell Cycle and Mitochondrial Activity of Leishmania donovani
by: Amrita Saha, et al.
Published: (2020-05-01)

New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxytocin
by: Veera C. S. R. Chittepu, et al.
Published: (2019-10-01)

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates High-fat Induced Cognitive Decline in Tauopathy Model Mice
by: Yuriko Nakaoku, et al.
Published: (2019-05-01)

Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2
by: Cynthia Melissa Valerio, et al.
Published: (2017-04-01)

Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees
by: Ji Yeon Lee, et al.
Published: (2017-09-01)